Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Youssef, Nermeen S ^a   Hakim, Sarah A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Breast carcinoma; Fascin; Immunohistochemistry; MMP 9

Indexed keywords

ACTIN BINDING PROTEIN; CARRIER PROTEIN; FASCIN; GELATINASE B; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; EGYPT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; EGYPT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICROFILAMENT PROTEINS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906834523     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-136     Document Type: Article

References (49)

1. Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom AC. Critical steps in hematogenous metastasis: an overview. Surg Oncol Clin N Am 2001, 10:243-255.
2. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M, Shimada Y. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005, 11(7):2597-2605.
3. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int J Biochem Cell Biol 2005, 37:1787-1804.
4. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. Fascins and their roles in cell structure and function. Bioessays 2002, 24:350-361.
5. Adams JC. Cell-matrix contact structures. Cell Mol Life Sci 2001, 58:371-392.
6. Pinkus GS, Pinkus JL, Langhoff E, Matsumura F, Yamashiro S, Mosialos G, Said JW. Fascin, a sensitive new marker for Reed- Sternberg cells of Hodgkin's disease. Evidence for a dendritic or B cell derivation?. Am J Pathol 1997, 150:543-562.
7. Ozerhan IH, Ersoz N, Onguru O, Ozturk M, Kurt B, Cetiner S. Fascin expression in colorectal carcinomas. Clinics (Sao Paulo) 2010, 65(2):157-164.
8. Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J. Fascin-1expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 2005, 36:741-746.
9. Maitra A, Iacobuzio-Donahue C, Rahman A, Sohn TA, Argani P, Meyer R, Yeo CJ, Cameron JL, Goggins M, Kern SE, Ashfaq R, Hruban RH, Wilentz RE. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 2002, 118:52-59.
10. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, Viale G. Independent prognostic value of fascin immunoreactivity in stage I non small cell lung cancer. Br J Cancer 2003, 88:537-547.
11. Kim SJ, Kim DC, Kim MC, Jung GJ, Kim KH, Jang JS, Kwon HC, Kim YM, Jeong JS. Fascin expression is related to poor survival in gastric cancer. Pathol Int 2012, 62:777-784.
12. Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsunoda S, Sato F, Martorell M, Garcia JA, Perez A, Shimada Y. Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines. Diagn Pathol 2010, 5:41.
13. Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med 2013, 11:52.
14. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is up regulated in hormone receptor negative breast cancer. Br J Cancer 2000, 83:870-873.
15. Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005, 11:186-192.
16. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006, 12:1533-1539.
17. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D, Adra C. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One 2011, 6:e27339.
18. Hayashi Y, Osanai M, Lee GH. Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci 2011, 102(6):1228-1235.
19. Onodera M, Zen Y, Harada K, Sato Y, Ikeda H, Itatsu K, Sato H, Ohta T, Asaka M, Nakanuma Y. Fascin is involved in tumor necrosis factor-a-dependent production of MMP9 in cholangiocarcinoma. Lab Invest 2009, 89:1261-1274.
20. Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, Yang ZM, Niu YD, Shen ZY, Li EM. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 2005, 337:355-362.
21. Toi M, Ishigaki S, Tominaga T. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 1998, 52:113-124.
22. Kato Y, Yamashita T, Ishikawa M. Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase- 9 and invasion ability of cervical cancer cells. Oncol Rep 2002, 9:565-569.
23. Zhang YG, Du J, Tian XX, Zhong YF, Fang WG. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J (Engl) 2007, 120(18):1597-1605.
24. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001, 84(11):1488-1496.
25. Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC. Expression and clinical significance of MMP-2, MMP-9, TIMP-1, and TIMP-2 in breast carcinoma. Ai Zheng 2003, 22(9):968-973.
26. Thanakit V, Sampatanukul P, Ruangvejvorachai P, Keelawat S. The association of co-expression of CD44v4/MMP-9 with different nodal status in high-grade breast carcinoma patients. J Med Assoc Thai 2005, 88(Suppl 4):S30-S35.
27. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North A 2003, 83:803-819.
28. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
29. Hsu SM, Raine L, Fanger H. Use of avidin -biotin - peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580.
30. Cheng H, Qin Y, Fan H, Su P, Zhang X, Zhang H, Zhou G. Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn Pathol 2013, 8:129.
31. Insall RH, Machesky LM. Actin dynamics at the leading edge: from simple machinery to complex networks. Dev Cell 2009, 17:310-322.
32. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997, 80:1529-1537.
33. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M, Adams JC. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 2003, 162:69-80.
34. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002, 12:319-328.
35. Alghanem AA, Hussain S. The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer. J Surg Oncol 1986, 31:218-221.
36. Clark GM, McGuire WL. Prognostic factors in primary breast cancer. Breast Cancer Res Treat 1983, 3:S69-S72.
37. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, Garcia M. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Mol Biol 1998, 65:163-168.
38. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 1999, 56:91-97.
39. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW, Yu D, Mooney EE, McCrea PD. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 2000, 19:4864-4875.
40. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621-7628.
41. Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006, 47(3):333-342.
42. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006, 95:65-72.
43. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, Giuliano A, Baumgartner K, Herrick J, Wolff RK. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One 2013, 8:e63165.
44. Liu Y, Xin T, Jiang QY, Huang DY, Shen WX, Li L, Lv YJ, Jin YH, Song XW, Teng C. CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol 2013, 30:366.
45. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004, 88:197-204.
46. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004, 88:75-85.
47. Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P. Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients. Chin J Oncol 2011, 33:381-384.
48. Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, Khan M. Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol 2014, 9:43.
49. Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 2011, 11:292.